Aptamer-Functionalized Nanovaccines: Targeting In Vivo DC Subsets for Enhanced Antitumor Immunity

• Published in: ACS applied materials & interfaces Vol. 15; no. 15; pp. 18590 - 18597
• Main Authors: Zheng, Liyan, Wu, Hui, Wen, Nachuan, Zhang, Yue, Wang, Zhimin, Peng, Xueyu, Tan, Yan, Qiu, Liping, Qu, Fengli, Tan, Weihong
• Format: Journal Article
• Language: English
• Published: United States American Chemical Society 19.04.2023
• Subjects: Adjuvants, Immunologic; Adjuvants, Pharmaceutic; Antigens, Neoplasm - genetics; Biological and Medical Applications of Materials and Interfaces; Cancer Vaccines; Dendritic Cells; Humans; Immunotherapy - methods; Neoplasms - therapy; T-Lymphocytes; nanovaccine; T cell activation; aptamer; DC subset-targeting; cancer immunoprevention
• ISSN: 1944-8244; 1944-8252
• DOI: 10.1021/acsami.2c20846

Cancer vaccines, which directly pulsed in vivo dendritic cells (DCs) with specific antigens and immunostimulatory adjuvants, showed great potential for cancer immunoprevention. However, most of them were limited by suboptimal outcomes, mainly owing to overlooking the complex biology of DC phenotypes. Herein, based on adjuvant-induced antigen assembly, we developed aptamer-functionalized nanovaccines for in vivo DC subset-targeted codelivery of tumor-related antigens and immunostimulatory adjuvants. We chose two aptamers, iDC and CD209, and tested their performance on DC targeting. Our results verified that these aptamer-functionalized nanovaccines could specifically recognize circulating classical DCs (cDCs), a subset of DCs capable of priming naïve T cells, noting that iDC outperformed CD209 in this regard. With excellent cDC-targeting capability, the iDC-functionalized nanovaccine induced potent antitumor immunity, leading to effective inhibition of tumor occurrence and metastasis, thus providing a promising platform for cancer immunoprevention.